Ackman, Other Allergan Shareholders, Ask for Special Meeting

Led by the company's largest shareholder, Bill Ackman, investors owning 31% of Botox manufacturer Allergan have called for a special shareholder meeting.

Ackman's investment vehicle, Pershing Square Capital Management, said it filed a lawsuit in the state of Delaware to require Allergan to schedule the meeting.

At the meeting, the activist shareholder hopes to replace the bulk of Allergan board members with his own slate of directors who might agree to the takeover deal and to force the pursued company to open discussions.

Pershing Square and Valeant Pharmaceutical International made a $52 billion hostile offer for Allergan in April. Since then Allergan has been fighting for investor support for its own stand-alone plan that includes cost cuts and making an acquisition of its own.

Meanwhile, Ackman, who has been working to sign up enough shareholders, said that under its bylaws Allergan is required now to call the meeting no later than Dec. 20.

Ackman and Valeant's cash and stock offer is now worth $49 billion, which Allergan said is not enough

The lawsuit is the latest legal tussle for the companies and follows Allergan's insider trading suit against Valeant and Ackman filed in a California federal court on Aug. 1.

Allergan said in a statement it would review the requests from shareholders in connection with Pershing Square's meeting request and report the results promptly after its review.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.